Merrimack
Jan 8, 2015

Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium

Other ASCO GI Presentations Include Preclinical and Clinical Data on MM-141 and MM-151

CAMBRIDGE, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that additional analyses from the Phase 3 NAPOLI-1 study of MM-398 (nanoliposomal irinotecan injection), also known as "nal-IRI," in metastatic pancreatic cancer will be presented at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium (ASCO GI), January 15-17, 2015 at Moscone West Building in San Francisco, CA. The data will be presented by Li-Tzong Chen, M.D., Ph.D., Director, Investigator and Attending Physician at the National Institute of Cancer Research in Taiwan.

Merrimack will also be presenting preclinical and clinical data supporting the development of MM-141 in combination with gemcitabine and nab-paclitaxel in front-line pancreatic cancer, as well as updated clinical and biomarker data from a Phase 1 trial of MM-151.

Oral Presentation

Oral Abstract Session: Cancers Of The Pancreas, Small Bowel, And Hepatobiliary Tract
Friday, January 16, 2015, 2:00 p.m. PT
Li-Tzong Chen, M.D., Ph.D., Director, Investigator and Attending Physician at the National Institute of Cancer Research in Taiwan
Poster viewing time: Friday, January 16, 2015, 12:00-2:00 p.m. and 5:30-7:00 p.m. PT

Poster Sessions

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack currently has six oncology therapeutics in clinical development and multiple candidates in preclinical development. For more information, please visit Merrimack's website at www.merrimackpharma.com or connect on Twitter at @MerrimackPharma.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

CONTACT: Media Contacts:



         Debbie Tseng

         Merrimack

         617-441-7659

         dtseng@merrimackpharma.com



         Liz Bryan

         Spectrum

         202-955-6222

         lbryan@spectrumscience.com



         Investor Contact:



         Geoffrey Grande, CFA

         Merrimack

         617-441-7602

         ggrande@merrimackpharma.com

Merrimack logo

Source: Merrimack Pharmaceuticals

News Provided by Acquire Media